Salud financiera de hoja de balance de PepGen

Salud financiera controles de criterios 6/6

PepGen tiene un patrimonio de los accionistas total de $134.0M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $156.3M y $22.3M respectivamente.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$132.30m
Patrimonio	US$133.98m
Total pasivo	US$22.32m
Activos totales	US$156.30m

Actualizaciones recientes sobre salud financiera

Artículo de análisis • Nov 19

Recent updates

Seeking Alpha • Mar 31

PepGen Plunges On Mixed Phase 2 Data, But Higher Dose Could Offer Some Relief

Summary PepGen Inc. shares plunged about 65% after mixed Phase 2 data for PGN-EDODM1 in DM1, with no functional improvement at 5 mg/kg. PGN-EDODM1 showed clean safety and biological activity, but efficacy was pretty modest and skewed by an outlier. So that higher 10 mg/kg dose is the next key catalyst. PEPG trades near cash value, reflecting heavy market skepticism on clinical success; the balance sheet supports operations through 2H26 and the next trial readout. I remain cautiously optimistic, awaiting 10 mg/kg data for clearer efficacy before considering new investment at these depressed levels. Read the full article on Seeking Alpha

Artículo de análisis • Nov 19

Is PepGen (NASDAQ:PEPG) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Artículo de análisis • Jun 27

Here's Why We're A Bit Worried About PepGen's (NASDAQ:PEPG) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Artículo de análisis • Mar 04

Here's Why We're Watching PepGen's (NASDAQ:PEPG) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Artículo de análisis • Nov 19

Here's Why We're Watching PepGen's (NASDAQ:PEPG) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Artículo de análisis • Aug 06

PepGen (NASDAQ:PEPG) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Seeking Alpha • Jul 31

PepGen: EDOs Could Enhance Dystrophin Expression Beyond Scope Of Current Treatments

Summary PepGen Inc. achieved positive data from the phase 2 CONNECT1 study, using PGN-EDO51 for the treatment of exon 51 skipping DMD patients; higher 10 mg/kg dosing of drug data is expected in early 2025. The global Duchenne Muscular Dystrophy treatment market size is expected to reach $8.19 billion in 2029. PGN-EDO53 is another EDO drug being developed by the company, with the goal of targeting 8% of DMD patients amenable to exon 53 skipping. Update on the use of PGN-EDODM1, in the ongoing phase 1 FREEDOM-DM1 study, expected in Q4 of 2024; Positive update could move the program towards a phase 2 trial. Read the full article on Seeking Alpha

Seeking Alpha • May 20

The Prognosis For PepGen

Summary PepGen's stock has experienced extreme volatility, with an 80% drop, a 370% rebound, and subsequent decline in 14 months. The rebound was driven by news that Sarepta's DMD exon 51 candidate had lower skipping output than PepGen's PGN-EDO51. PepGen is focused on developing oligonucleotide therapies for severe neuromuscular and neurologic diseases, with two programs in human trials. A full investment analysis around PepGen follows in the paragraphs below. Read the full article on Seeking Alpha

Seeking Alpha • Jan 20

PepGen: Long Road Ahead

Summary PepGen is using exon skipping therapies to address muscular dystrophy conditions, specifically Duchenne muscular dystrophy (DMD) and Myotonic dystrophy type 1 (DM1). They are developing PGN-EDO51 and PGN-EDODM1. The market sizes for these therapies are estimated to be around $1.3 billion for DMD and potentially up to $4.5 billion for DM1, but there are financial and operational risks involved. Valuation doesn't offer enough of a margin of safety. Read the full article on Seeking Alpha

Artículo de análisis • Nov 13

Will PepGen (NASDAQ:PEPG) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Artículo de análisis • Jul 31

Will PepGen (NASDAQ:PEPG) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Artículo de análisis • Dec 31

We Think PepGen (NASDAQ:PEPG) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($134.3M) de PEPG superan a sus pasivos a corto plazo ($9.0M).

Pasivo a largo plazo: Los activos a corto plazo de PEPG ($134.3M) superan a sus pasivos a largo plazo ($13.4M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: PEPG está libre de deudas.

Reducción de la deuda: PEPG no ha tenido ninguna deuda en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: PEPG tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: PEPG dispone de suficiente cash runway para 1.1 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 29.1% cada año.

Descubre empresas con salud financiera

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2026/07/01 05:11
Precio de las acciones al final del día	2026/07/01 00:00
Beneficios	2026/03/31
Ingresos anuales	2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también contamos con guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

PepGen Inc. está cubierta por 9 analistas. 7 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
Tazeen Ahmad	BofA Global Research
Adam Vogel	Craig-Hallum Capital Group LLC
Debjit Chattopadhyay	Guggenheim Securities, LLC

Salud financiera de hoja de balance de PepGen

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Is PepGen (NASDAQ:PEPG) In A Good Position To Deliver On Growth Plans?

Here's Why We're A Bit Worried About PepGen's (NASDAQ:PEPG) Cash Burn Situation

Here's Why We're Watching PepGen's (NASDAQ:PEPG) Cash Burn Situation

Here's Why We're Watching PepGen's (NASDAQ:PEPG) Cash Burn Situation

PepGen (NASDAQ:PEPG) Is In A Good Position To Deliver On Growth Plans

Will PepGen (NASDAQ:PEPG) Spend Its Cash Wisely?

Recent updates

New minor risk - Market cap size

PepGen Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

PepGen Inc., Annual General Meeting, Jun 18, 2026

New major risk - Share price stability

PepGen Plunges On Mixed Phase 2 Data, But Higher Dose Could Offer Some Relief

PepGen Inc Announces Regulatory Updates On Freedom2 Trial

Price target increased by 8.6% to US$10.86

Price target increased by 7.0% to US$10.17

Pepgen Inc. Appoints Joseph Vittiglio as Chief Business and Legal Officer, Effective December 8, 2025

Is PepGen (NASDAQ:PEPG) In A Good Position To Deliver On Growth Plans?

Price target increased by 21% to US$11.50

Price target increased by 16% to US$9.50

Price target increased by 22% to US$8.33

PepGen Inc. has completed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Share price stability

PepGen Inc.(NasdaqGS:PEPG) dropped from Russell 2500 Growth Index

Here's Why We're A Bit Worried About PepGen's (NASDAQ:PEPG) Cash Burn Situation

Pomerantz Law Firm Announces the Filing of A Class Action Against Pepgen Inc

Price target decreased by 31% to US$8.00

PepGen Inc. to Focus on Development of Promising DM1 Program Following 10 mg/Kg PGN-EDO51 Update

Price target decreased by 7.8% to US$11.80

PepGen Inc., Annual General Meeting, Jun 04, 2025

PepGen Inc. Announces Appointment of Two New Directors to Its Board

PepGen Announces Update to Phase 2 CONNECT2-EDO51 Study in Patients with DMD

Here's Why We're Watching PepGen's (NASDAQ:PEPG) Cash Burn Situation

New major risk - Share price stability

Pepgen Inc. Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1

Price target decreased by 21% to US$12.80

PepGen Inc. Announces CONNECT Program Updates

New major risk - Shareholder dilution

New minor risk - Market cap size

Insufficient new directors

Price target decreased by 9.4% to US$15.40

PepGen Inc. Announces Clinical Hold in the U.S. on IND Application to Initiate Connect2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy

Here's Why We're Watching PepGen's (NASDAQ:PEPG) Cash Burn Situation

Price target decreased by 13% to US$17.00

New major risk - Revenue and earnings growth

PepGen Inc. Announces Christopher Ashton to Retire from Its Board of Directors, Effective September 30, 2024

New major risk - Share price stability

PepGen Inc. Appoints Paul Streck as Executive Vice President, Head of Research & Development, Head of Research & Development

Price target decreased by 9.3% to US$19.60

PepGen (NASDAQ:PEPG) Is In A Good Position To Deliver On Growth Plans

Chief Medical Officer exercised options and sold US$61k worth of stock

PepGen: EDOs Could Enhance Dystrophin Expression Beyond Scope Of Current Treatments

PepGen Inc. Announces Positive Data from Low-Dose Cohort of Pgn-Edo51 in Ongoing Connect1-Edo51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular Dystrophy

Chief Medical Officer exercised options and sold US$72k worth of stock

PepGen Inc. Appoints Afsaneh Mohebbi as SVP, Portfolio and Program Management and Dave Borah as SVP, Investor Relations and Corporate Communications

Chief Medical Officer exercised options and sold US$74k worth of stock

Pepgen Inc. Announces Executive Promotions

Insider notifies of intention to sell stock

The Prognosis For PepGen

Senior Vice President of Chemistry notifies of intention to sell stock

PepGen Inc., Annual General Meeting, Jun 20, 2024

PepGen Inc. Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

PepGen Inc. Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1

PepGen Inc. has completed a Follow-on Equity Offering in the amount of $80.08155 million.

New minor risk - Shareholder dilution

New major risk - Share price stability

Price target decreased by 14% to US$20.00

PepGen: Long Road Ahead

Mary Beth DeLena Joins PepGen as General Counsel and Secretary

Pepgen Inc. Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of P GN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping

Pepgen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)

PepGen Inc. Announces Appointment of Howard Mayer, M.D. to Board of Directors

Will PepGen (NASDAQ:PEPG) Spend Its Cash Wisely?

New major risk - Revenue and earnings growth

PepGen Inc. Announces FDA Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)

PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Company's Enhanced Delivery Oligonucleotide Platform and PGN-EDO Program at Two Medical Conferences

New major risk - Share price stability